Wordt geladen...
IL-2, the next best thing in chronic GVHD therapy?
In this issue of Blood, Koreth et al have reported that interleukin-2 (IL-2) is effective in chronic graft-versus-host disease (cGVHD) patients who had failed up to two prior lines of therapy.(1)
Bewaard in:
| Gepubliceerd in: | Blood |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4937357/ https://ncbi.nlm.nih.gov/pubmed/27389542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-05-711796 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|